Your session is about to expire
← Back to Search
This trial is looking at the efficacy and safety of two different drugs in combination with pembrolizumab for people with NSCLC who have been treated with anti-PD-L1 therapy before.
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You have cancer that has spread to your brain or the lining of your brain.You have had lung inflammation in the past that needed steroids to treat, or you currently have lung inflammation.You have a specific type of lung cancer called non-squamous NSCLC and you cannot receive a targeted therapy that is already approved for your condition.You have another type of cancer that has been getting worse or needed treatment in the past 2 years.You have a condition where your immune system attacks your own body and you have needed strong medication to treat it in the last 2 years.You have received a transplant of someone else's tissue or organ.You have already received treatment with a certain type of medication called an anti-PD-(L)1 monoclonal antibody, either by itself or with other similar medications, but your condition did not improve.You have had a serious allergic reaction to monoclonal antibodies, like pembrolizumab, or any of the substances used in them.You have mental health or substance abuse issues that may make it difficult for you to follow the study's instructions.You have had radiation therapy to the lung with a high dose within the past 6 months.
- Group 1: Pembrolizumab + Boserolimab
- Group 2: Pembrolizumab + MK-4830
- Group 3: Pembrolizumab + MK-0482
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What other medical research has been conducted with Pembrolizumab?
"Pembrolizumab was first studied in 2004 at the Clinical Addictions Research Laboratory. Since then, there have been 1010 completed trials and 1114 active studies recruiting patients. Many of these are based in Lexington, Kentucky."
Are investigators still looking for new participants for this experiment?
"No, this study is not currently enrolling patients. The trial was initially posted on January 21st, 2020 and the most recent edit was made on October 31st, 2022. There are 2508 other trials that may be recruiting at this time."
Could you tell me how many different hospitals are testing this new medication?
"There are 18 clinical trial sites running this particular study, including the University of Kentucky Markey Cancer Center (Site 0019) in Lexington, Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (Site 0034) in New York, and University of California San Francisco (Site 0007) in Washingtonf Californ in New York, and University of California San Francisco (Site 0007) in Washington. Other locations include:"
What are some conditions that Pembrolizumab has been shown to be effective for?
"Pembrolizumab is an effective treatment for unresectable melanoma, microsatellite instability high, and catarrh."
Has Pembrolizumab been cleared by the FDA?
"Pembrolizumab falls into the category of a Phase 2 trial medication, so there is some evidence backing its safety. However, because it is still in clinical trials there is no data to support its efficacy."
Share this study with friends